Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:01:25.363Z.
Calculation as of: 2026-10-06T15:01:25.363Z.
Quote observation: 2026-10-06T15:00:33.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 92e82853ec35d591c91e1857ba5f245e9338475f566e1ab86be3b7c1b83139db
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Artiva Biotherapeutics, Inc.
Market Cap
$346.77M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$352.79M
Price/FCF Ratio
N/A
TTM Avg
54.19
3Y Avg
39.66
5Y Avg
37.45
Market Cap
$356.03M
Price/FCF Ratio
N/A
TTM Avg
6.69
3Y Avg
6.69
5Y Avg
6.69
Market Cap
$336.05M
Price/FCF Ratio
N/A
TTM Avg
114347.68
3Y Avg
114347.68
5Y Avg
114347.68
Market Cap
$356.59M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | $346.77M | N/A | N/A | N/A | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $352.79M | N/A | 54.19 | 39.66 | 37.45 |
| Opus Genetics, Inc. (IRD)vs › | $353.38M | N/A | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $354.48M | 2.15 | 2.83 | 26.37 | 19.21 |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $356.03M | N/A | 6.69 | 6.69 | 6.69 |
| Agenus Inc. (AGEN)vs › | $336.05M | N/A | 114347.68 | 114347.68 | 114347.68 |
| Ocugen, Inc. (OCGN)vs › | $356.07M | N/A | N/A | N/A | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $356.59M | N/A | N/A | N/A | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $333.12M | N/A | N/A | N/A | N/A |
| C4 Therapeutics, Inc. (CCCC)vs › | $324.51M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
